— Lysosomal storage disorders result in severe, multi-system dysfunction and frequently, early death. Currently, a number of lysosomal storage disorders are treated with enzyme replacement therapy (ERT), which requires periodic infusions of the deficient enzyme. However, in a number of instances the…
— Background: Alzheimer’s disease (AD) is the 6th leading cause of death in the United States, and yet causation of the disease is poorly understood and targets for therapeutic intervention are still being identified. Recently, mutations in the immune receptor TREM2 have been found to be strongl…
— Dr. Hiroko Yano and Dr. Albert Kim, and their research teams at the Washington University School of Medicine in St. Louis developed and extensively evaluated a novel therapeutic approach using DNMT inhibitors to treat Huntington’s Disease (HD) and other neurodegenerative disorders. Currently D…
— Background
Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
— The monoclonal antibodies developed are agaonistic monoclonal antibodies. These antibodies can help in enhancing the immune system by activating dendritic cell subsets. Furthermore, these antibodies are unique, as they can activate Dendritic cells without the need for cross-linking the receptor.
| Name | # Summaries | Author | Action |
|---|---|---|---|
| 15 | |||
| 13 | |||
| 1 | |||
| 15 | |||
| 26 | |||
| 14 | |||
| 14 |
Creating...
